#France #Artificial Intelligence #Google Cloud #Servier #Suresnes

Servier and Google Cloud Expand Partnership

In a major development for the pharmaceutical industry, Servier, an independent international pharmaceutical group, has announced an expansion of its partnership with Google Cloud. This collaboration, which now extends for five additional years, is aimed at harnessing the power of AI and generative AI to streamline the research and development of innovative therapeutic solutions for patients. The announcement was made on January 16, 2025, highlighting a significant step forward for both organizations in their commitment to advancing healthcare through technology.

Accelerating Research and Development

Historically, the drug development process can take nearly 15 years, making it crucial for pharmaceutical companies to optimize their research methodologies. At Servier, this optimization is achieved through the integration of advanced digital technologies and scientific innovation. By leveraging Google Cloud's AI capabilities, Servier aims to express new therapeutic outcomes and reduce the time it takes to bring drugs from conception to market.

"At Servier, we strongly believe that the synergy between innovative science and digital advancement is essential for delivering effective treatments to patients rapidly and with personalized care," stated Claude Bertrand, Executive Vice President of Research & Development and Chief Scientific Officer at Servier. The partnership with Google Cloud enhances Servier's ability to access and analyze vast datasets effectively, which is instrumental in identifying potential therapeutic targets and subsections of patients who are likely to respond well to new treatments.

A Multifaceted Approach to AI

The partnership has laid out approximately 60 identified use cases for generative AI that can expedite drug development. These include:

• - Early Research and Screening: Identifying new therapeutic targets.
• - Clinical Trials Optimization: Digital management of clinical trials, which encompasses patient recruitment and remote management.
• - Success Probability Enhancement: Increasing the chances of drug candidates succeeding in development phases.
• - Regulatory Efficiency: Streamlining regulatory affairs management.
• - Sustainability Efforts: Predictive maintenance for production processes and supply chain optimization to reduce environmental impacts.

According to Servier, the use of generative AI is seen as a robust tool to advance the precision of medicine, thus enabling quicker development of tailored therapeutic solutions. The effective use of artificial intelligence technologies will allow Servier to maximize efficiencies across its entire operation, from R&D to distribution, ultimately affecting patient outreach positively.

Enhanced Employee Engagement

To further support their ambitions, Servier is equipping its workforce with effective tools powered by Google’s generative AI technologies, which include cutting-edge models like Gemini. This initiative not only boosts productivity across various teams within the organization but also adheres strictly to data security standards and confidentiality protocols.

Virginie Dominguez, Executive Vice President of Digital Data and Information Systems at Servier, emphasized this commitment, saying, "By integrating Google Cloud AI solutions comprehensively throughout our operational framework, we reaffirm our dedication to enhancing therapeutic innovation aimed solely at accelerating and improving research for patient benefit."

Looking Towards the Future

Through this collaboration, Servier expresses optimism about the future. Shweta Maniar, Global Director of Healthcare & Life Sciences at Google Cloud, shared her excitement about the advancements this partnership promises. "We are witnessing Servier transition from exploration to tangible production results in a responsible manner with clear focus on ethics and confidentiality," she noted.

Beyond its immediate goals in cardiology, Servier is also placing a strategic focus on oncology, particularly targeting difficult-to-treat cancers, and continues to invest substantially in R&D, dedicating over 70% of its budget in this field.

With headquarters in France, and an operational footprint extending over 150 countries, Servier's commitment to innovation and patient-centric care is set to transform not only its internal processes but also the broader healthcare landscape.

As they move forward in collaboration with Google Cloud, the pharmaceutical giant is poised to make significant strides in how therapies are developed, ensuring patients receive advanced and personalized healthcare solutions more efficiently than ever before.

For more information, visit servier.com and follow them on social media platforms.